Cenegermin

Cenegermin

Cenegermin

Pharmaceutical drug

Cenegermin, sold under the brand name Oxervate, also known as recombinant human nerve growth factor (rhNGF), is a recombinant form of human nerve growth factor (NGF). In July 2017, it was approved in the European Union as an eye drop formulation for the treatment of moderate or severe neurotrophic keratitis in adults.[5][1]

Quick Facts Clinical data, Trade names ...

As a recombinant form of NGF, cenegermin is a peripherally selective agonist of the TrkA and LNGFR (p75NTR) which must be administered parenterally.[6]

The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.[7]

History

It was developed by Anabasis Pharma, Dompé Farmaceutici, and Ospedale San Raffaele.[6]

Research

In addition to neurotrophic keratitis, cenegermin is also under development for the treatment of dry eyes, retinitis pigmentosa, and glaucoma.[6]

References

  1. [1]
    World Health Organization (2017). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 77". WHO Drug Information. 31 (1): 76. hdl:10665/330984.
  2. [2]
    "AusPAR: Cenegermin". Therapeutic Goods Administration (TGA). 23 December 2019. Archived from the original on 1 November 2021. Retrieved 26 August 2020.
  3. [3]
    "Oxervate APMDS". Therapeutic Goods Administration (TGA). 26 May 2022. Retrieved 10 March 2024.
  4. [4]
    "Summary Basis of Decision (SBD) for Oxervate". Health Canada. 23 October 2014. Retrieved 29 May 2022.
  5. [5]
    "Oxervate EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 25 August 2020.
  6. [6]
    "Cenegermin - Dompe Farmaceutici - AdisInsight". adisinsight.springer.com. Retrieved 2020-06-05.
  7. [7]
    New Drug Therapy Approvals 2018 (PDF). U.S. Food and Drug Administration (FDA) (Report). January 2019. Retrieved 16 September 2020.

Further reading
Share this article:

This article uses material from the Wikipedia article Cenegermin, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.